US Stock Market Move | Collaborating with BP Pulse to mutually open up the charging network, XPeng, Inc. ADR Sponsored Class A (XPEV.US) rose nearly 9% in pre-market trading.
On Tuesday, Xpeng Motors (XPEV.US) shares rose nearly 9% in pre-market trading, reaching $12.86.
On Tuesday, XPeng, Inc. ADR Sponsored Class A (XPEV.US) pre-market trading rose nearly 9%, reaching $12.86. In terms of news, XPeng, Inc. ADR Sponsored Class A announced that Xpeng Charging and bp pulse have signed a Memorandum of Understanding (MOU) to open up their respective charging networks to each other. The two parties will create pilot projects in some key economic zones in mainland China, with coordinated equipment and locations to establish a fast charging network in core cities, providing electric vehicle users with a safer and more reliable charging experience. It is reported that customers from both sides will have access to a widely distributed charging network in over 420 cities in mainland China with over 30,000 charging stations, working together to create one of the highest quality charging networks in core city areas.
Related Articles
.png)
Goldman Sachs: Raises target price of SENSETIME-W (00020) to HK$3.09, maintains "buy" rating

HK Stock Market Move | JINGCHENG MAC (00187) increased by over 5%, affiliated with Beijing Bawei to support the world's first tower-type solar thermal replacement project for ultra-heavy oil extraction being put into operation.

Innovative drug blockbuster! Arvinas (ARVN.US) collaborates with Pfizer Inc. (PFE.US) to advance the third-party commercialization of "breast cancer ER degrader."
Goldman Sachs: Raises target price of SENSETIME-W (00020) to HK$3.09, maintains "buy" rating
.png)
HK Stock Market Move | JINGCHENG MAC (00187) increased by over 5%, affiliated with Beijing Bawei to support the world's first tower-type solar thermal replacement project for ultra-heavy oil extraction being put into operation.

Innovative drug blockbuster! Arvinas (ARVN.US) collaborates with Pfizer Inc. (PFE.US) to advance the third-party commercialization of "breast cancer ER degrader."
